DexCom heads into its Q1 2026 earnings report with options markets flashing their most cautious signal in months.
The put/call ratio jumped to 1.05 on the day of the print — nearly three standard deviations above its 20-day average of 0.88, and the highest defensive reading in nearly a year. That spike stands out even more given that the ratio had been remarkably steady in the 0.84–0.90 range for most of May. The demand for downside protection arrived alongside a strong price run: DXCM gained 17% over the past month and 7.6% on the week, closing at $72.01. Options traders appear to be hedging a stock that has moved a long way quickly.
Short interest tells a calmer story. At roughly 4.9% of the free float — around 19.1 million shares — the position is meaningful but not extreme. It has grown about 26% over the past month in share terms, largely tracking the price rally rather than signalling new conviction from bears. Borrow conditions offer no fuel for a squeeze: availability is exceptionally loose at nearly 2,923% of short interest, meaning shares to borrow vastly outnumber existing shorts. Cost to borrow has edged lower to around 0.37%, its cheapest level in weeks. The lending market is wide open.
The analyst debate has sharpened into a clear pattern: bulls still outnumber bears, but targets have been coming down. Last week, BofA Securities maintained its Buy rating while cutting its target from $100 to $80. Canaccord Genuity mirrored the move, slashing from $100 to $82 while staying positive. Barclays, the lone Underweight voice in the mix, trimmed its target further to $64. The direction of travel from the Street is consistent — positive on the structural story, more selective on near-term valuation after the recent run. The bull case centres on mid-teens revenue growth through 2028, expanding non-intensive Type 2 diabetes adoption, and a management team with a track record of execution. Bears point to pressure from the G7 wear-time transition, where margin benefits may not materialise until 2027 or later, and to growing international competition compressing the premium the market is willing to pay. EPS momentum scores rank in the 82nd percentile on a 30-day view, and the company has a strong recent habit of beating estimates — ranking in the 71st percentile on EPS surprise. The PE has expanded roughly 11% over the past month to around 26x, a re-rating that concentrates attention on whether the current growth rate justifies it.
Past prints have been rewarding: the last two earnings events each produced gains of roughly 5–7% on the day and continued running higher over the following week. The Q1 report tonight is therefore less a test of the underlying growth narrative — widely accepted on both sides — and more a referendum on whether the raised bar implied by a 17% pre-earnings move is one DexCom's guidance can clear.
See the live data behind this article on ORTEX.
Open DXCM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
